{"id":61321,"date":"2025-05-27T10:03:09","date_gmt":"2025-05-27T08:03:09","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/"},"modified":"2025-05-27T10:03:09","modified_gmt":"2025-05-27T08:03:09","slug":"3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/","title":{"rendered":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance<\/i><\/p>\n<p class=\"bwalignc\">\n<i>The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company&#8217;s path to sustainable value creation<\/i><\/p>\n<p class=\"bwalignc\">\n<i>The persistent failure to address compliance issues risks alienating its customers and could lead to irreversible damage to corporate value<\/i><\/p>\n<p class=\"bwalignc\">\n<i>To resolve these problems, we strongly urge shareholders to vote against the reappointment of Mr. Hiromi Edahiro, Mr. Yoshiaki Kamoya and Mr. Hidehito Kotani at the upcoming Annual General Meeting<\/i><\/p>\n<p>TOKYO&#8211;(BUSINESS WIRE)&#8211;3D Investment Partners Pte. Ltd., the investment manager of 3D Opportunity Master Fund (collectively referred to as \u201c3D\u201d or \u201cwe,\u201d meaning either or both of 3D Investment Partners Pte. Ltd. and 3D OPPORTUNITY MASTER FUND), today released a shareholder presentation highlighting the ongoing and serious corporate governance failures at Toho Holdings Co., Ltd. (\u201cToho HD\u201d or the \u201cCompany\u201d) (TOKYO: 8129). The presentation outlines in detail the reasons why 3D recommends shareholders vote against the reappointment of Representative Director, President and CFO Hiromi Edahiro (\u201cMr. Edahiro\u201d) and, Outside Director Yoshiaki Kamoya (\u201cMr. Kamoya\u201d) and Hidehito Kotani (\u201cMr. Kotani\u201d).<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/4\/LOGO.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/4\/LOGO.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/21\/LOGO.jpg\"><\/a><\/p>\n<p>\nLink to presentation: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.3dipartners.com%2Fengagement%2Ftoho-maximizing-corporate-value-en-202505.pdf&amp;esheet=54260179&amp;newsitemid=20250525116649&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.3dipartners.com%2Fengagement%2Ftoho-maximizing-corporate-value-en-202505.pdf&amp;index=1&amp;md5=1432a1270186185c0a68f1a1ba3a485b\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.3dipartners.com\/engagement\/toho-maximizing-corporate-value-en-202505.pdf<\/a><\/p>\n<p>\n3D has been a shareholder of Toho HD since 2020 and currently holds approximately 22%<sup>1<\/sup> of the voting rights, making it one of the Company\u2019s largest shareholders. Over the past two years, 3D has engaged in constructive dialogue with Toho HD with the sole aim of enhancing long-term corporate value.<\/p>\n<p>\n<sup>1<\/sup> Calculated as: (Number of shares held by us + Number of potential shares from convertible bonds with stock acquisition rights held by us) \u00f7 (Total number of issued shares \u2013 Treasury shares + Number of potential shares from convertible bonds with stock acquisition rights held by us).<\/p>\n<p>\n<span class=\"bwuline\">Management Issues at Toho HD<\/span><\/p>\n<p>\n3D believes that the fundamental management challenges facing Toho HD\u2014specifically, the low profitability of its core business and an inefficient balance sheet\u2014stem from a serious deficiency in its corporate governance structure. In August 2023, we submitted concrete proposals to address these management issues to Toho HD, which were disclosed in our press release dated March 25, 2025. However, due to Toho HD\u2019s dysfunctional governance, the Board of Directors was unable to objectively evaluate and implement recommendations which would improve the Company\u2019s profitability and value. As a result, the majority of our proposals were dismissed, and the underlying issues remain unresolved.<\/p>\n<p>\nAs long as this governance failure persists, we believe that these management challenges will remain unresolved and long-term corporate value growth will continue to be impaired.<\/p>\n<p>\n<span class=\"bwuline\">Repeated Scandals and Involvement in the Nihon University Incident<\/span><\/p>\n<p>\nToho HD has been subject to administrative sanctions for its involvement in bid-rigging on three separate occasions. Nevertheless, the Company has never conducted a thorough investigation of these scandals led by independent experts and has consistently avoided addressing the root causes of its misconduct.<\/p>\n<p>\nIn addition to the bid-rigging incidents, it has recently come to light that Toho HD was involved in a fraudulent scheme related to Nihon University Hospital (the \u201cNihon University Incident\u201d). In this case, a part of funds that should have been returned from Toho HD as purchase rebates were instead funneled to third parties by the Company through fictitious consulting contracts, and resulting in the illicit payments. The Company was obviously able to notice that the scheme involved such clear compliance violations at the time of execution since another peer company reportedly refused to participate.<\/p>\n<p>\n<span class=\"bwuline\">An attitude that is suspected as <\/span><span class=\"bwuline\">Concealment<\/span><\/p>\n<p>\nDespite the seriousness of the Nihon University Incident, Toho HD has failed to provide any public explanation. Statements made by Mr. Edahiro during media interviews are in conflict with case records, raising serious concerns about the credibility and transparency of his explanations. Moreover, Toho HD has refused our request to establish a third-party investigative committee that is independent from the Company. Furthermore, during meetings we have had with the Company, senior executives (<i>Shikkoyakuin<\/i>) have asked us to refrain from further inquiries. This response, among others, can only be interpreted as attempts to conceal the truth.<\/p>\n<p>\nToho HD&#8217;s assertion that &#8220;There was no legal violation,&#8221; and the decision to take no further action, do not meet the standards of governance required for a listed company. What shareholders are demanding is not the mere absence of illegality, but the presence of sufficient transparency and a sound governance framework necessary for long-term corporate value creation.<\/p>\n<p>\n<span class=\"bwuline\">Risks of Irreparable Damage to Corporate Value<\/span><\/p>\n<p>\nThe Board\u2019s continued failure to address the Company\u2019s compliance issues threatens to erode trust among business partners, potentially leading to revenue losses. This poses the risks of irreparable damage to corporate value. Based on its unwillingness to address these serious issues, we believe the Board of Directors is fundamentally unfit to enhance corporate value.<\/p>\n<p>\n<span class=\"bwuline\">Our Recommendation Regarding Voting at the General Meeting<\/span><\/p>\n<p>\nIn light of the urgent need to rectify Toho HD\u2019s governance failures, we strongly recommend that shareholders vote against the reappointment of Mr. Edahiro (Representative Director, President, and CFO), Mr. Kamoya and Mr. Kotani (Outside Directors) for the following reasons:<\/p>\n<p>\nRegarding Mr. Edahiro:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nHe was centrally involved in the management of the companies, which are Toho HD or its subsidiary involved in two prior bid-rigging scandals as well as the Nihon University Incident, and must be held accountable for the ongoing governance failures.<\/li>\n<li>\nHis public statements have critically contradicted case records, raising serious concerns about the credibility and transparency of his explanations.<\/li>\n<li>\nHe was appointed CEO without any external comparison or being held accountable for past scandals, through an internal succession process that lacks transparency.<\/li>\n<\/ul>\n<p>\nRegarding Mr. Kamoya:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDespite being the longest-serving outside director, he is not a member of the Special Committee on Governance Enhancement, reflecting a troubling indifference toward governance and compliance issues.<\/li>\n<li>\nAlthough he should have taken a central role in the Nomination Committee as a previous chairperson thereof, he did not even try to pursue the responsibilities for the past scandals and failed to fulfill his responsibilities of exercising proper oversight in selecting a qualified successor CEO. Furthermore, the internal CEO succession process lacked transparency and, to our knowledge, no attempt was made to look for and evaluate outside candidates.<\/li>\n<li>\nHe currently serves as an advisor to a company with which Toho HD holds cross-shareholdings, casting significant doubt on his independence.<\/li>\n<\/ul>\n<p>\nRegarding Mr. Kotani:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nAs a member of the Nomination Committee, he was involved in last year\u2019s process of appointing Mr. Edahiro as CEO.<\/li>\n<li>\nFurthermore, this year, regarding the decision to reappoint Mr. Edahiro as CEO, Mr. Kotani has not fulfilled his responsibilities as a chairperson of the Nomination Committee who should play the key role of the committee. The internal CEO succession process lacked transparency and, to our knowledge, no attempt was made to look for and evaluate outside candidates.<\/li>\n<\/ul>\n<p>\n<span class=\"bwuline\">To Shareholders<\/span><\/p>\n<p>\nAs outlined above, we understand that Toho HD is suffering from a critical failure of governance, which in our view has led to the neglect of pressing management issues, the loss of growth opportunities, and significant risk of value destruction due to unresolved compliance concerns.<\/p>\n<p>\nWe respectfully urge shareholders to review our presentation and support the restoration of sound governance and sustainable long-term value creation at Toho HD by voting against the reappointment of Mr. Edahiro, Mr. Kamoya and Mr. Kotani at the Company\u2019s upcoming Annual General Meeting.<\/p>\n<p>\n<b>About 3D Investment Partners Pte. Ltd.<\/b><\/p>\n<p>\n3D Investment Partners Pte. Ltd. is an independent Singapore-based Japan focused value investing fund manager founded in 2015. 3D Investment Partners Pte. Ltd. focuses on partnering with management[s] who share its investment philosophy of medium- to long-term value creation through compound capital growth and a common objective of achieving long-term returns.<\/p>\n<p>\n<b>Disclaimer<\/b><\/p>\n<p>\nThis press release, including annexes is provided for informational purposes only and does not constitute an offer to purchase or sell any security or investment product, nor does it constitute professional or investment advice. This press release should not be relied on by any person for any purpose and is not, and should not be construed as investment, financial, legal, tax or other advice.<br \/>\n<br \/>3D Investment Partners Pte. Ltd. and its affiliates and related persons (\u201c3DIP\u201d) of either believe that the current market price of Toho HD does not reflect its intrinsic value. 3DIP acquired beneficial and\/or economic interests based on its own idea that Toho HD securities have been undervalued and provide an attractive investment opportunity and may in the future beneficially own, and\/or have an economic interest in, Toho HD securities. 3DIP intends to review its investments in Toho HD on a continuing basis and, depending upon various factors including, without limitation, Toho HD&#8217;s financial position and strategic direction, the outcome of any discussions with Toho HD, overall market conditions, other investment opportunities available to 3DIP, and the availability of Toho HD securities at prices that would make the purchase or sale of Toho HD securities desirable, 3DIP may, from time to time (in the open market or in private transactions), buy, sell, cover, hedge, or otherwise change the form or substance of any of its investments (including the investment in Toho HD securities) to any degree in any manner permitted by any applicable law, and expressly disclaims any obligation to notify others of any such changes.<\/p>\n<p>\n3DIP provides no representation or warranty, either expressed or implied, in relation to the accuracy, completeness, or reliability of the information contained herein (including content or quotes from news coverage or other third-party public sources (\u201cThird-Party Materials\u201d)), nor is it intended to be a complete statement or summary of the securities, markets, or developments referred to herein. 3DIP expressly disclaims any responsibility or liability for any loss whatsoever arising from any use of, or reliance on, this press release or its contents as a whole or in part by any person, or otherwise whatsoever arising in connection with this press release. 3DIP hereby expressly disclaims any obligation to update or provide additional information regarding the contents of this press release or to correct any inaccuracies in the information contained in this press release.<\/p>\n<p>\n3DIP disclaims any intention or agreement to be treated as a joint holder (<i>kyodo hoyu sha<\/i>) under the Financial Instruments and Exchange Act of Japan, a closely related party (<i>missetsu kankei sha<\/i>) under the Foreign Exchange and Foreign Trade Act with other shareholders, or receiving any power or permission to represent other shareholders in relation to the exercise of their voting rights, and has no intention to solicit, encourage, induce or require any person to cause other shareholders to represent such voting rights.<\/p>\n<p>\n3DIP does not have the intention to make a proposal, directly or through other shareholders of Toho HD, to transfer or abolish the business or assets of Toho HD and\/or Toho HD group companies at the general shareholders meeting of Toho HD. 3DIP does not have the intention or purpose to engage in any conduct which constricts the continuing and stable implementation of business of Toho HD and\/or Toho HD group companies.<\/p>\n<p>\nThis press release may include Third-Party Materials. Permission to quote from Third-Party Materials in this press release may neither have been sought nor obtained. The content of the Third-Party Materials has not been independently verified by 3DIP and does not necessarily represent the views of 3DIP. The authors and\/or publishers of the Third-Party Materials are independent of, and may have different views to 3DIP. Quoting Third-Party Materials in this press release does not imply that 3DIP endorses or concurs with any part of the content of the Third-Party Materials or that any of the authors or publishers of the Third-Party Materials endorses or concurs with any views which have been expressed by 3DIP on the relevant subject matter. The Third-Party Materials may not be representative of all relevant news coverage or views expressed by other third parties on the stated issues.<\/p>\n<p>\nIn respect of information that has been prepared by 3DIP (and not otherwise attributed to any other party) and which appears in the English language version of this press release, in the event of any inconsistency between the English language version and the Japanese language version of this press release, the meaning of the Japanese language version shall prevail unless otherwise expressly indicated.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nKRIK (PR Agent)<br \/>\n<br \/>Koshida: +81-70-8793-3990<br \/>\n<br \/>Sugiyama: +81-70-8793-3989<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company&#8217;s path to sustainable value creation The persistent failure to address compliance issues risks alienating its &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61321","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company&#8217;s path to sustainable value creation The persistent failure to address compliance issues risks alienating its ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-27T08:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting\",\"datePublished\":\"2025-05-27T08:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/\"},\"wordCount\":2085,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250525116649\\\/en\\\/2479613\\\/22\\\/LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/\",\"name\":\"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250525116649\\\/en\\\/2479613\\\/22\\\/LOGO.jpg\",\"datePublished\":\"2025-05-27T08:03:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250525116649\\\/en\\\/2479613\\\/22\\\/LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250525116649\\\/en\\\/2479613\\\/22\\\/LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/","og_locale":"en_US","og_type":"article","og_title":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend","og_description":"Repeated scandals, an attitude that is suspected as concealment and a lack of succession planning at Toho HD indicate its serious breakdown in corporate governance The Board of Directors continues to reject reasonable proposals for operational improvement, obstructing the Company&#8217;s path to sustainable value creation The persistent failure to address compliance issues risks alienating its ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/","og_site_name":"Pharma Trend","article_published_time":"2025-05-27T08:03:09+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting","datePublished":"2025-05-27T08:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/"},"wordCount":2085,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/","url":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/","name":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg","datePublished":"2025-05-27T08:03:09+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250525116649\/en\/2479613\/22\/LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/3d-investment-partners-recommends-toho-holdings-shareholders-vote-against-the-reappointment-of-ceo-hiromi-edahiro-and-outside-director-yoshiaki-kamoya-and-hidehito-kotani-at-the-companys-77t\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"3D Investment Partners Recommends Toho Holdings Shareholders Vote Against the Reappointment of CEO Hiromi Edahiro, and Outside Director Yoshiaki Kamoya and Hidehito Kotani at the Company\u2019s 77th Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61321"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61321\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}